Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study

Journal of Clinical Oncology

Volumn 28, Issue 12, 2010, Pages 2051-2057

  Perry, James R ^a   Bélanger, Karl ^a   Mason, Warren P ^a   Fulton, Dorcas ^a   Kavan, Petr ^a   Easaw, Jacob ^a   Shields, Claude ^a   Kirby, Sarah ^a   Macdonald, David R ^a   Eisenstat, David D ^a   Thiessen, Brian ^a   Forsyth, Peter ^a   Pouliot, Jean François ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; CORTICOSTEROID; DEXAMETHASONE; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE; DRUG DERIVATIVE;

ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CANCER SURVIVAL; DRUG EFFICACY; DRUG SAFETY; FATIGUE; GLIOBLASTOMA; HERPES ZOSTER; HUMAN; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MYCOSIS; NAUSEA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; VOMITING; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; BRAIN TUMOR; CANADA; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; GLIOMA; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROSPECTIVE STUDY; RECURRENT DISEASE; TIME; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CANADA; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; GLIOMA; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 77951648272     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.5520     Document Type: Article

References (40)

1. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005 (Pubitemid 40349501)
2. Mirimanoff RO, Gorlia T, Mason W, et al: Radiotherapy and temozolomide for newly diagnosed glioblastoma: Recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24:2563-2569, 2006 (Pubitemid 46630635)
3. Stupp R, Hegi ME, Mason WP, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466, 2009
4. Catapano CV, Broggini M, Erba E, et al: In vitro and in vivo methazolastone-induced DNA damage and repair in L-1210 leukemia sensitive and resistant to chloroethylnitrosoureas. Cancer Res 47:4884-4889, 1987
5. Tisdale MJ: Antitumor imidazotetrazines-XV: Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones. Biochem Pharmacol 36:457-462, 1987
6. Taverna P, Catapano CV, Citti L, et al: Influence of O6-methylguanine on DNA damage and cytotoxicity of temozolomide in L1210 mouse leukemia sensitive and resistant to chloroethylnitrosoureas. Anticancer Drugs 3:401-405, 1992
7. Pegg AE, Dolan ME, Moschel RC: Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol 51: 167-223, 1995
8. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003, 2005 (Pubitemid 40349502)
9. Hau P, Koch D, Hundsberger T, et al: Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma. Neurology 68:688-690, 2007 (Pubitemid 46667817)
10. Villano JL, Seery TE, Bressler LR: Temozolomide in malignant gliomas: Current use and future targets. Cancer Chemother Pharmacol 64:647-655, 2009
11. Bower M, Newlands ES, Bleehan NM, et al: Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 40:484-488, 1997 (Pubitemid 27389289)
12. Brandes AA, Ermani M, Basso U: Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: A phase II study. Ann Oncol 12:255-257, 2001 (Pubitemid 32223878)
13. Brada M, Hoang-Xuan K, Rampling R, et al: Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12:259-266, 2001 (Pubitemid 32223879)
14. Brandes AA, Ermani M, Basso U, et al: Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: A phase II study. Oncology 63:38-41, 2002 (Pubitemid 34977935)
15. Khan RB, Raizer JJ, Malkin MG, et al: A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro Oncol 4:39-43, 2002 (Pubitemid 34269465)
16. Tolcher AW, Gerson SL, Denis L, et al: Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88:1004-1011, 2003 (Pubitemid 36560766)
17. Brandes AA, Tosoni A, Cavallo G, et al: Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: Phase II study from Gruppo Italiano Cooperative Din Euro- Oncologia (GICNO). Br J Cancer 95:1155-1160, 2006 (Pubitemid 44658477)
18. Kesari S, Schiff D, Drappatz J, et al: Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res 15:330-337, 2009
19. Kerbel RS, Kamen BA: The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer: 4:423-436, 2004 (Pubitemid 38745528)
20. Bertolini F, Paul S, Mancuso P, et al: Maximum tolerable dose and low- dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63:4342-4346, 2003 (Pubitemid 36951001)
21. Emmenegger U, Man S, Shaked Y, et al: A comparative analysis of low dose metronomic cyclophosphamide reveals absent of low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res 64:3994-4000, 2004 (Pubitemid 38697315)
22. Bocci G, Francia G, Man S, et al: Thrombospondin-1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A 100:12917-12922, 2003 (Pubitemid 37340000)
23. Kurzen H, Schmitt S, Naher H, et al: Inhibition of angiogenesis by non-toxic doses of temozolomide. Anticancer Drugs 14:515-522, 2003 (Pubitemid 37083156)
24. Tuettenberg J, Grobholz R, Korn T, et al: Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme. J Cancer Res Clin Oncol 131:31-40, 2005
25. Perry JR, Rizek P, Cashman R, et al: Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: The rescue approach. Cancer 113:2152-2157, 2008
26. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000 (Pubitemid 30099779)
27. National Institutes of Health. Common Terminology Criteria for Adverse Events, version 3.0, August 9, 2006. http://ctep.cancer.gov/protocolDevelopment/ electronic-applications/docs/ctcaev3.pdf
28. Vlassenbroeck I, Califice S, Diserens AC, et al: Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 10:332-337, 2008 (Pubitemid 352019119)
29. Wong ET, Hess KR, Gleason MJ, et al: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572-2578, 1999 (Pubitemid 29368260)
30. Martinez R, Schackert G, Yaya-Tur R, et al: Frequent hypermethylation of the DNA repair gene MGMT in long-term survivors of glioblastoma multi-forme. J Neurooncol 83:91-93, 2007 (Pubitemid 46647170)
31. Donson AM, Addo-Yobo SO, Handler MH, et al: MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood Cancer 48:403-407, 2007 (Pubitemid 46340105)
32. Paz MF, Yaya-Tur R, Rojas-Marcos I, et al: CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 10:4933-4938, 2004 (Pubitemid 39099766)
33. Brandes AA, Franceschi E, Tosoni A, et al: Change in MGMT methylation status between first and second surgery for recurrence: Clinical implications. J Clin Oncol 27:15s, 2009 (suppl; abstr 2027)
34. Brandwein JM, Yang L, Schimmer AD, et al: A phase II study of temozolomide therapy for poor-risk patients aged [gteq] 60 years with acute myeloid leukemia: Low levels of MGMT predict for response. Leukemia 21:821-824, 2007 (Pubitemid 46444575)
35. Bokstein F, Shpigel S, Blumenthal DT: Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer 112:2267-2273, 2008 (Pubitemid 351628638)
36. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722-4729, 2007 (Pubitemid 350086473)
37. Poulsen HS, Grunnet K, Sorensen M, et al: Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. Acta Oncol 48:52-58, 2009
38. Batchelor TT, Sorensen AG, di Tomaso E, et al: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83-95, 2007 (Pubitemid 46075199)
39. Happold C, Roth P, Wick W, et al: ACNU-based chemotherapy for recurrent glioma in the temozolomide era. J Neurooncol 92:45-48, 2009
40. Maron R, Vredenburgh JJ, Desjardins A, et al: Bevacizumab and daily temozolomide for recurrent glioblastoma multiforme (GBM). J Clin Oncol 26:47-52, 2008